Abstract
Attention deficit hyperactivity disorder (ADHD) used to be considered a mild childhood condition that manifested mostly in the school setting and remitted by adolescence. More recently, a large body of evidence has shown that it is a very frequent psychiatric problem in childhood, causes considerable suffering in patients and their families, and persists into adulthood in one form or other 50 - 70% of the time. This chapter outlines current pharmacological treatment options available to clinicians who wish to provide treatment for ADHD. Each US Food and Drug Administration (FDA)-approved agent is reviewed in detail focusing on the safety profile and efficacy data, as well as the monitoring tools that can be utilized to optimize treatment. Alternative non FDA-approved options are outlined as well. This review also addresses recent controversies in the field and provides practical clinical advice within a Frequently Asked Question format.
Original language | English |
---|---|
Title of host publication | Clinical Aspects of Psychopharmacology in Childhood and Adolescence, Second Edition |
Publisher | Nova Science Publishers, Inc. |
Pages | 51-75 |
Number of pages | 25 |
ISBN (Electronic) | 9781536102536 |
ISBN (Print) | 9781536102413 |
State | Published - 1 Jan 2016 |